TELEFLEX INC (TFX): Results of Operations and Financial Condition
TELEFLEX INC (TFX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE August 6, 2026 Teleflex Reports Second Quarter Finan cial Results and Full Year 2026 Outlook Completes Sale of OEM Business and Will Deploy Net Proceeds to Reduce Debt and Repurchase Common Stock Announces $250 Million Accelerated Share Repurcha
How this was made
The 30-second read
Why it matters
Key trading inputs are the guidance reductions (GAAP revenue growth and GAAP EPS) alongside an increase in adjusted diluted EPS, plus a scheduled $250M accelerated share repurchase and refinancing/debt actions. Product/regulatory and clinical pipeline updates (EZPLAZ BLA approval, Freesolve trial milestones) add longer-horizon optionality but are secondary to the near-term guidance and integration timing.
Market read
This is a decision-grade update combining earnings/guidance, a scheduled buyback tranche, and a stated reason for revenue outlook pressure (Biotronik integration taking longer).
What to watch
The guidance assumptions explicitly include transition services margin and exclude certain items (tariff refunds, discontinued operations), so traders should normalize comparisons to continuing-ops and adjusted metrics before extrapolating.
Teleflex Reports Second Quarter Financial Results and Full Year 2026 Outlook; Completes Sale of OEM Business and Will Deploy Net Proceeds to Reduce Debt and Repurchase Common Stock
Continuing-operations revenue increased 28.9% and adjusted diluted EPS increased to $1.76, but GAAP diluted EPS declined to $0.96, GAAP operating margin declined to 12.8%, and the company reduced its 2026 revenue and GAAP EPS outlook because Biotronik Vascular Intervention integration is taking longer than expected.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Q2 2026 revenue from continuing operationsGAAP | $570.3 million | – | 28.9% |
| Q2 2026 pro forma adjusted revenue from continuing operationsnon-GAAP | $570.3 million | – | 4.7% pro forma adjusted constant currency revenue growth |
| Q2 2026 gross margin from continuing operationsGAAP | 58.2% | – | – |
| Q2 2026 adjusted gross margin from continuing operationsnon-GAAP | 61.7% | – | – |
| Q2 2026 selling, general and administrative expenses from continuing operationsGAAP | $213,515 (Dollars in thousands) | – | – |
| Q2 2026 research and development expenses from continuing operationsGAAP | $45,122 (Dollars in thousands) | – | – |
| Q2 2026 operating margin from continuing operationsGAAP | 12.8% | – | – |
| Q2 2026 adjusted operating margin from continuing operationsnon-GAAP | 19.6% | – | – |
| Q2 2026 income from continuing operations before interest, taxes and loss on extinguishment of debtGAAP | $72,824 (Dollars in thousands) | – | – |
| Q2 2026 income from continuing operationsGAAP | $41,762 (Dollars in thousands) | – | – |
| Q2 2026 net incomeGAAP | $99,693 (Dollars in thousands) | – | – |
| Q2 2026 diluted earnings per share from continuing operationsGAAP | $0.96 | – | – |
| Q2 2026 adjusted diluted earnings per share from continuing operationsnon-GAAP | $1.76 | – | – |
| Q2 2026 effective income tax rate from continuing operationsGAAP | 7.5% | – | – |
| Q2 2026 adjusted effective income tax rate from continuing operationsnon-GAAP | 9.9% | – | – |
| Six months ended June 30, 2026 revenue from continuing operationsGAAP | $1,118.6 million | – | 30.6% |
| Six months ended June 30, 2026 pro forma adjusted revenue from continuing operationsnon-GAAP | $1,118.6 million | – | 4.9% pro forma adjusted constant currency revenue growth |
| Six months ended June 30, 2026 gross margin from continuing operationsGAAP | 57.1% | – | – |
| Six months ended June 30, 2026 adjusted gross margin from continuing operationsnon-GAAP | 61.5% | – | – |
| Six months ended June 30, 2026 operating margin from continuing operationsGAAP | 8.3% | – | – |
| Six months ended June 30, 2026 adjusted operating margin from continuing operationsnon-GAAP | 18.8% | – | – |
| Six months ended June 30, 2026 income from continuing operationsGAAP | $36,924 (Dollars in thousands) | – | – |
| Six months ended June 30, 2026 net incomeGAAP | $91,539 (Dollars in thousands) | – | – |
| Six months ended June 30, 2026 diluted earnings per share from continuing operationsGAAP | $0.84 | – | – |
| Six months ended June 30, 2026 adjusted diluted earnings per share from continuing operationsnon-GAAP | $3.14 | – | – |
| Six months ended June 30, 2026 net cash provided by operating activities from continuing operationsGAAP | $138,559 (Dollars in thousands) | – | – |
| Six months ended June 30, 2026 expenditures for property, plant and equipmentGAAP | $(32,825) (Dollars in thousands) | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Vascular, Q2 2026Management cited excellent performance in its Vascular business. | $246.3 million | – | 9.0% reported revenue growth; 8.0% pro forma adjusted constant currency revenue growth |
| Interventional, Q2 2026Reported growth reflects the acquired Vascular Intervention business in the prior-year pro forma comparison; management said integration is progressing but taking longer than expected. | $211.9 million | – | 86.1% reported revenue growth; (1.0)% pro forma adjusted constant currency revenue growth |
| Surgical, Q2 2026Management cited excellent performance in its Surgical business. | $112.1 million | – | 9.1% reported revenue growth; 9.2% pro forma adjusted constant currency revenue growth |
| Vascular, six months ended June 30, 2026No additional segment-specific driver was reported. | $483.2 million | – | 8.6% reported revenue growth; 6.4% pro forma adjusted constant currency revenue growth |
| Interventional, six months ended June 30, 2026Prior-year pro forma adjustments include Vascular Intervention and discontinued products. | $416.5 million | – | 94.6% reported revenue growth; 0.9% pro forma adjusted constant currency revenue growth |
| Surgical, six months ended June 30, 2026Prior-year pro forma adjustments include discontinued products. | $218.9 million | – | 10.7% reported revenue growth; 9.6% pro forma adjusted constant currency revenue growth |
full year 2026 continuing operations outlook
- RevenueGAAP revenue $2,260 to $2,280; GAAP revenue growth 13.40% to 14.40%; pro forma adjusted constant currency revenue growth 3.50% to 4.50%
- NoteGAAP diluted earnings per share from continuing operations $2.54 to $2.84
- NoteAdjusted diluted earnings per share from continuing operations $6.90 to $7.20
- NoteApproximately 19% adjusted operating margin for 2026 inclusive of transition services associated with the close of the OEM Strategic Divestiture
- NoteEstimate of an approximately 0.70% positive impact of foreign exchange rate fluctuations on GAAP revenue growth
- NoteGuidance excludes expected benefits from transition services and manufacturing services agreements associated with the Acute Care and Interventional Urology Strategic Divestiture
- NoteGuidance excludes the impact of the announced $250 million Accelerated Share Repurchase and other anticipated future repurchases under the previously announced $1 billion share repurchase program
- NoteAdjusted diluted EPS guidance excludes any impact of potential IEEPA tariff refunds
Capital returns
- Repurchased 1.9 million shares of common stock for $250 million through open market transactions during the second quarter at an average price per share of $130.85.
- $750 million remained available under the $1 billion share repurchase authorization as of June 30, 2026.
- The company intends to commence an accelerated share repurchase of $250 million of common stock, effective August 7, 2026.
- Dividends paid were $29,830 (Dollars in thousands) for the six months ended June 30, 2026, compared to $30,218 (Dollars in thousands) for the prior-year period.
What drove it
- Q2 Vascular revenue grew 9.0% reported and 8.0% on a pro forma adjusted constant currency basis.
- Q2 Surgical revenue grew 9.1% reported and 9.2% on a pro forma adjusted constant currency basis.
- The company received FDA BLA approval in late July for EZPLAZ Freeze Dried Plasma.
- The company completed enrollment ahead of schedule in the BIOMAG-II Freesolve study and initiated the U.S. BIOMAG-III pivotal trial, with first patient procedures completed in June.
- The completed OEM divestiture is intended to support debt reduction, shareholder returns and investment in growth opportunities.
Concerns
- The company reduced full-year 2026 GAAP revenue growth guidance to 13.40% to 14.40% and pro forma adjusted constant currency revenue growth guidance to 3.50% to 4.50%.
- Management said integration of the acquired Biotronik Vascular Intervention business is taking longer than expected and updated revenue outlook accordingly.
- Q2 GAAP operating margin was 12.8%, compared to 20.6% in the prior-year period; adjusted operating margin was 19.6%, compared to 24.8%.
- Q2 GAAP diluted EPS from continuing operations was $0.96, compared to $1.54 in the prior-year period.
- Q2 Interventional pro forma adjusted constant currency revenue growth was (1.0)%.
What to watch
- Execution of mitigation actions related to elongated Biotronik Vascular Intervention integration timelines.
- Delivery against the full-year 2026 pro forma adjusted constant currency revenue growth outlook of 3.50% to 4.50%.
- Progress toward the approximately 19% adjusted operating margin assumption for 2026.
- Use of OEM divestiture proceeds, including the planned $250 million accelerated share repurchase effective August 7, 2026.
- Freesolve clinical milestones, including the BIOMAG-II data readout positioned for late 2027.
Balance sheet and cash flow
- Total cash, cash equivalents and restricted cash equivalents were $316.9 million at June 30, 2026, compared to $402.7 million at December 31, 2025.
- Cash and cash equivalents were $300,159 (Dollars in thousands) at June 30, 2026, compared to $378,564 (Dollars in thousands) at December 31, 2025.
- Net accounts receivable were $364.6 million at June 30, 2026, compared to $345.6 million at December 31, 2025.
- Inventories were $351.9 million at June 30, 2026, compared to $404.4 million at December 31, 2025.
- Current borrowings were $87,500 (Dollars in thousands) and long-term borrowings were $2,720,509 (Dollars in thousands) at June 30, 2026.
- The company completed the OEM divestiture for $1.5 billion in cash and estimates after-tax proceeds of approximately $1.25 billion.
- The company paid off its $700 million Term Loan A-2 associated with the Biotronik Vascular Intervention acquisition.
- Net cash provided by operating activities from continuing operations was $138,559 (Dollars in thousands) for the six months ended June 30, 2026, compared to net cash used in operating activities from continuing operations of $(9,296) (Dollars in thousands) in the prior-year period.
- Net cash used in investing activities from continuing operations was $(81,367) (Dollars in thousands), compared to $(46,562) (Dollars in thousands) in the prior-year period.
- Net cash used in financing activities from continuing operations was $(126,985) (Dollars in thousands), compared to $(83,192) (Dollars in thousands) in the prior-year period.
Analysis
Teleflex reported Q2 continuing-operations revenue of $570.3 million, up 28.9% reported from $442.5 million. The acquisition-driven reported increase contrasts with 4.7% pro forma adjusted constant currency growth. Vascular and Surgical each posted high-single-digit pro forma adjusted constant currency growth of 8.0% and 9.2%, respectively. Interventional revenue rose 86.1% reported, but declined (1.0)% on the pro forma adjusted constant currency basis.
Profitability was lower than the prior-year period on both reported and adjusted measures. GAAP gross margin was 58.2% versus 60.1%, while adjusted gross margin was 61.7% versus 64.5%. GAAP operating margin fell to 12.8% from 20.6%, and adjusted operating margin fell to 19.6% from 24.8%. GAAP diluted EPS from continuing operations declined to $0.96 from $1.54, whereas adjusted diluted EPS increased to $1.76 from $1.73.
For the first six months, continuing-operations revenue was $1,118.6 million, up 30.6% reported, with 4.9% pro forma adjusted constant currency growth. Net cash provided by operating activities from continuing operations was $138,559 (Dollars in thousands), compared with net cash used in operating activities of $(9,296) (Dollars in thousands) in the prior-year period. Cash, cash equivalents and restricted cash equivalents were $316.9 million at June 30, 2026.
Capital allocation was a central feature of the release. Teleflex completed the OEM divestiture for $1.5 billion in cash, estimated after-tax proceeds of approximately $1.25 billion, and paid off its $700 million Term Loan A-2. It repurchased 1.9 million shares for $250 million in the second quarter and plans a further $250 million accelerated share repurchase effective August 7, 2026. The company also refinanced its credit agreement and issued $500 million aggregate principal amount of 5.875% senior notes due 2032.
The outlook was reduced for revenue and GAAP EPS because integration of the acquired Biotronik Vascular Intervention business is taking longer than expected. Full-year GAAP revenue growth guidance is now 13.40% to 14.40%, and pro forma adjusted constant currency revenue growth guidance is 3.50% to 4.50%. In contrast, adjusted diluted EPS guidance was increased to $6.90 to $7.20, reflecting capital allocation actions including second-quarter share repurchases and repayment of the Term Loan A-2. The company assumes approximately 19% adjusted operating margin for 2026 inclusive of OEM-divestiture transition services.
Management, verbatim
We delivered a strong second quarter, led by excellent performance in our Vascular and Surgical businesses, while continuing to take decisive actions to strengthen the company for the future.
Jason Weidman, President and Chief Executive Officer
Integration of the acquired Biotronik Vascular Intervention business is progressing, though taking longer than expected, and we updated our revenue outlook accordingly.
Jason Weidman, President and Chief Executive Officer
I’m encouraged by the progress our team is making across the organization. Looking ahead, I am focused on completing a thorough assessment of the business and sharpening our strategic and operating plan to maximize shareholder value.
Jason Weidman, President and Chief Executive Officer
Not in the filing
stated, not guessed- Prior-quarter comparisons for reported operating metrics were not provided.
- Free cash flow was not reported.
- Quarterly operating cash flow and capital expenditures were not reported.
- Full-year 2026 gross-margin, operating-expense and tax-rate guidance were not provided.
- A previous-release outlook was not provided; therefore no comparison of actual results with prior guidance is available.
- Segment operating income and segment margins were not reported.
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Teleflex filed an SEC 8-K with Q2 2026 results for continuing operations, updated 2026 outlook, and capital allocation updates following completion of its OEM divestiture.
Ticker impact
Teleflex reported Q2 results and cut 2026 GAAP revenue and EPS guidance while raising adjusted EPS, plus announced a $250M accelerated buyback starting Aug 7.
Moderate volatility around the guidance cut and buyback details; upside bias if investors focus on adjusted EPS increase and OEM proceeds/deleveraging.
The filing contains multiple decision-relevant datapoints: Q2 continuing-ops revenue/EPS, updated 2026 guidance ranges, OEM divestiture proceeds and term-loan payoff, and a scheduled accelerated repurchase effective Aug 7. The main uncertainty is the longer-than-expected Biotronik integration delay, which directly affects the revenue outlook.
Market effects
Could influence sentiment for medical device peers via read-through on vascular/surgical demand and integration execution risk.
Primarily US-listed large-cap medtech sentiment; limited direct regional spillover.
FDA approval (EZPLAZ) and ongoing scaffold trial progress may support broader global medtech innovation narratives, but the dominant driver is company-specific guidance.
Counterpoint
Investors may over-discount the revenue outlook cut if adjusted EPS guidance rises and OEM proceeds plus deleveraging improve earnings quality and flexibility.
Key entities
- companyTeleflex Incorporated
Reported Q2 2026 continuing-operations results, updated 2026 guidance, completed OEM divestiture, and announced a $250M accelerated share repurchase.
- counterpartyMontagu and Kohlberg
Buyers of Teleflex's OEM business for $1.5B cash, generating proceeds used for debt reduction and capital return.
- regulatorU.S. Food and Drug Administration
Approved Teleflex's EZPLAZ Freeze Dried Plasma BLA in late July.
